


## CTLA4 Inhibitor Inhibitors (inhibitors, agonists and modulators)



CTLA-4, short for Cytotoxic T-Lymphocyte-Associated protein 4 and also called CD152. The first immunecheckpoint receptor to be clinically targeted, is expressed exclusively on T cells where it primarily regulates the amplitude of the early stages of T cell activation.



### CTLA-4 inhibitor - CAS 635324-72-0


**Catalog Number:** B0084-284810

**Price:** \$198/10 mg

**Molecular Weight:** 427.363

**Molecular Formula:** C<sub>21</sub>H<sub>13</sub>F<sub>4</sub>N<sub>5</sub>O

**Description:** CTLA-4 inhibitor is an inhibitor of CTLA-4, an immune checkpoint negatively regulating T cell function. CTLA-4 is thought to regulate T-cell proliferation early in an immune response, primarily in lymph nodes.



### Tremelimumab - CAS 745013-59-6

**Catalog Number:** 745013-59-6

**Molecular Weight:**

**Molecular Formula:**

**Description:** A human immunoglobulin (Ig) G2 monoclonal antibody directed against the human T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4), with potential immune checkpoint inhibitory and antineoplastic activities. Tremelimumab binds to CTLA4 on activated T-lymphocytes and blocks the binding of the antigen-presenting cell ligands B7-1 (CD80) and B7-2 (CD86) to CTLA4, resulting in inhibition of CTLA4-mediated downregulation of T-cell activation.

### Ipilimumab - CAS 477202-00-9

**Catalog Number:** B0084-244929

**Molecular Weight:**

**Molecular Formula:** C<sub>67</sub>H<sub>42</sub>H<sub>99</sub>72N<sub>17</sub>32O<sub>200</sub>4S<sub>4</sub>O

**Description:** Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells.


### MK-0668 - CAS 865110-07-2

**Catalog Number:** 865110-07-2

**Molecular Weight:** 685.59

**Molecular Formula:** C<sub>31</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>6</sub>S

**Description:** MK-0668 is an antagonist of very late antigen-4 with picomolar, whole blood activity and slow dissociation rates were discovered by incorporating an amino substituent on the proline fragment of the initial lead structure.



**MK-0668 mesylate - CAS 865111-04-2**

**Catalog Number:** 865111-04-2

**Molecular Weight:** 781.69      **Molecular Formula:** C<sub>31</sub>H<sub>30</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>6</sub>S.CH<sub>4</sub>O<sub>3</sub>S

**Description:** MK-0668 is an antagonist of very late antigen-4 with picomolar, whole blood activity and slow dissociation rates were discovered by incorporating an amino substituent on the proline fragment of the initial lead structure.

